Metabolomic Profiling Distinction of Human Nonalcoholic Fatty Liver Disease Progression from a Common Rat Model

被引:42
作者
Han, JianHua [1 ,2 ]
Dzierlenga, Anika L. [1 ]
Lu, Zhengqiang [3 ]
Billheimer, Dean D. [3 ]
Torabzadeh, Elmira [3 ]
Lake, April D. [1 ]
Li, Hui [1 ]
Novak, Petr [4 ]
Shipkova, Petia [5 ]
Aranibar, Nelly [5 ]
Robertson, Donald [5 ]
Reily, Michael D. [5 ]
Lehman-McKeeman, Lois D. [5 ]
Cherrington, Nathan J. [1 ]
机构
[1] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China
[3] Univ Arizona, Arizona Stat Consulting Lab, Tucson, AZ USA
[4] Biol Ctr CAS, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic
[5] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Princeton, NJ USA
基金
美国国家卫生研究院;
关键词
BILE-ACIDS; TRANSPORTER EXPRESSION; CHOLINE; STEATOSIS; PATHOLOGY; TOXICITY;
D O I
10.1002/oby.21855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Characteristic pathological changes define the progression of steatosis to nonalcoholic steatohepatitis (NASH) and are correlated to metabolic pathways. A common rodent model of NASH is the methionine and choline deficient (MCD) diet. The objective of this study was to perform full metabolomic analyses on liver samples to determine which pathways are altered most pronouncedly in this condition in humans, and to compare these changes to rodent models of nonalcoholic fatty liver disease (NAFLD). Methods: A principal component analysis for all 91 metabolites measured indicated that metabolome perturbation is greater and less varied for humans than for rodents. Results: Metabolome changes in human and rat NAFLD were greatest for the amino acid and bile acid metabolite families (e.g., asparagine, citrulline, gamma-aminobutyric acid, lysine); although, in many cases, the trends were reversed when compared between species (cholic acid, betaine). Conclusions: Overall, these results indicate that metabolites of specific pathways may be useful biomarkers for NASH progression, although these markers may not correspond to rodent NASH models. The MCD model may be useful when studying certain end points of NASH; however, the metabolomics results indicate important differences between humans and rodents in the biochemical pathogenesis of the disease.
引用
收藏
页码:1069 / 1076
页数:8
相关论文
共 33 条
  • [1] New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Ali, Rafeeq
    Cusi, Kenneth
    [J]. ANNALS OF MEDICINE, 2009, 41 (04) : 265 - 278
  • [2] Molecular pathways in non-alcoholic fatty liver disease
    Berlanga, Alba
    Guiu-Jurado, Esther
    Antonio Porras, Jose
    Auguet, Teresa
    [J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 221 - 238
  • [3] Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models
    Canet, Mark J.
    Hardwick, Rhiannon N.
    Lake, April D.
    Dzierlenga, Anika L.
    Clarke, John D.
    Cherrington, Nathan J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) : 586 - 595
  • [4] Bile acids: regulation of synthesis
    Chiang, John Y. L.
    [J]. JOURNAL OF LIPID RESEARCH, 2009, 50 (10) : 1955 - 1966
  • [5] Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression
    Corbin, Karen D.
    Zeisel, Steven H.
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (02) : 159 - 165
  • [6] Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
    Fisher, Craig D.
    Lickteig, Andrew J.
    Augustine, Lisa M.
    Ranger-Moore, James
    Jackson, Jonathan P.
    Ferguson, Stephen S.
    Cherrington, Nathan J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (10) : 2087 - 2094
  • [7] Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats
    Fisher, Craig D.
    Lickteig, Andrew J.
    Augustine, Lisa M.
    Elferink, Ronald P. J. Oude
    Besselsen, David G.
    Erickson, Robert P.
    Cherrington, Nathan J.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 613 (1-3) : 119 - 127
  • [8] Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method
    Garcia-Canaveras, Juan C.
    Teresa Donato, M.
    Castell, Jose V.
    Lahoz, Agustin
    [J]. JOURNAL OF LIPID RESEARCH, 2012, 53 (10) : 2231 - 2241
  • [9] Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease
    Gentile, Christopher L.
    Nivala, Angela M.
    Gonzales, Jon C.
    Pfaffenbach, Kyle T.
    Wang, Dong
    Wei, Yuren
    Jiang, Hua
    Orlicky, David J.
    Petersen, Dennis R.
    Pagliassotti, Michael J.
    Maclean, Kenneth N.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2011, 301 (06) : R1710 - R1722
  • [10] NEW INSIGHT INTO THE BIOCHEMICAL PATHOLOGY OF LIVER IN CHOLINE DEFICIENCY
    GHOSHAL, AK
    [J]. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 30 (04) : 263 - 273